If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() Clinical GeneticsVolume 72 Issue 4, Pages 288 - 295 Published Online: 2 Sep 2007 © 2010 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 173K) | Related Articles | Citation Tracking Review The genetics of mitral valve prolapse Copyright 2007 The Authors Journal compilation KEYWORDS genetic profile • mitral regurgitation • mitral valve prolapse • prevalence Grau JB, Pirelli L, Yu P-J, Galloway AC, Ostrer H. The genetics of mitral valve prolapse. ABSTRACTMitral valve prolapse (MVP) is a very common clinical condition that refers to a systolic billowing of one or both mitral valve leaflets into the left atrium. Improvements of echocardiographic techniques and new insights in mitral valve anatomy and physiology have rendered the diagnosis of this condition more accurate and reliable. MVP can be sporadic or familial, demonstrating autosomal dominant and X-linked inheritance. Three different loci on chromosomes 16, 11 and 13 have been found to be linked to MVP, but no specific gene has been described. Another locus on chromosome X was found to cosegregate with a rare form of MVP called 'X-linked myxomatous valvular dystrophy'. MVP is more frequent in patients with connective tissue disorders including Marfan syndrome, Ehlers–Danlos and osteogenesis imperfecta. The purpose of this review is to describe previous studies on the genetics and prevalence of MVP. The report warrants the need for further genetically based studies on this common, albeit not fully understood, clinical entity. Received 9 April 2007, revised and accepted for publication 25 May 2007 |